Successful Partnership Between MAIA Biotechnology and Cromos Pharma MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate. Read more in the press release: https://www.pr.com/press-release/914337
Cromos Pharma’s Country Head Speaks at GCP Training Event in Istanbul We are thrilled to share that Seniz Sagol, Cromos Pharma’s Country Head for Türkiye, represented our team as a speaker at a prominent industry event in Istanbul this week. The one-day GCP Training, accredited by the Ministry of Health, was a collaborative effort alongside Memorial Hospital Group, the Association of Research-Based Pharmaceutical Companies (AIFD), and
Cromos Pharma’s Strategic Meeting in Miami Last week, Cromos Pharma US executive team gathered in Miami for a full-day strategy session. This meeting was aimed at reinforcing our collaborative spirit and refining our business approaches. More than just a conventional meeting, it was a great chance for our team members to build stronger bonds and share important ideas We wrapped up
